

Table of Contents

■ SECTION I: Fundamentals of US Medical Device Regulations

Chapter 1:	History of Food, Drug, and Cosmetic Laws	1
	<i>Updated by Karen Zhou, JD, MS, RAC-Devices</i>	
Chapter 2:	Regulatory Pathways for Medical Devices and Combination Products.....	15
	<i>Updated by Michael R. Hamrell, PhD, RAC, FRAPS, RQAP-GCP, CCRA, FACRP</i>	
Chapter 3:	Clinical Trials: GCPs, Regulations, and Compliance for Drugs, Biologics, and Medical Devices	35
	<i>Updated by Monique Carter, MS, RAC</i>	
Chapter 4:	FDA Communications and CDRH Meetings	81
	<i>Updated by Susan Resnick, PhD and Amy Tezel, PhD</i>	
Chapter 5:	Current Good Manufacturing Practices and Quality System Design.....	91
	<i>Updated by Richard Vincins, CQP MCQI, CMDA, CQA, RAC-Devices</i>	
Chapter 6:	FDA User Fees	103
	<i>Updated by Michelle J. Rubin-Onur, PhD and Anike K. Freeman, MEng, PMP</i>	
Chapter 7:	Regulatory Strategy	109
	<i>Updated by Karen Fan, MSc, RAC, PEng, PMP</i>	
Chapter 8:	Medical Device Submissions	117
	<i>Updated by Allison Komiyama, PhD, RAC-US and Erin Gontang, PhD</i>	
Chapter 9:	Medical Device Compliance and Postmarketing Activities	153
	<i>Updated by Ryan Burke, RAC-CAN, RAC-EU, RAC-Global, RAC-US and Elizabeth Goldstein, RAC-US</i>	
Chapter 10:	In Vitro Diagnostics Submissions and Compliance.....	167
	<i>Updated by Jocelyn Jennings, MS, RAC-US, RAC-Drugs, RAC-Devices</i>	
Chapter 11:	Labeling, Advertising, and Promotion for Medical Devices and In Vitro Diagnostics.....	179
	<i>Updated by Carol M. Cooper, MS, RAC, IM (ASCP), RM (AAM)</i>	
Chapter 12:	Combination Products.....	191
	<i>Updated by Jocelyn Jennings, MS, RAC-US, RAC-Drugs, RAC-Devices</i>	
Abbreviations and Acronyms		205
Glossary of Terms.....		209
Index.....		219

Figures

Figure 2-1	Decision Tree for Drug, Biologic, and Device Development and Approval When FDA Premarket Review is Required	21
Figure 3-1	Types of Pharmaceutical and Biologic Clinical Trials and Typical Pathway.....	47
Figure 3-2	Types of Medical Device Clinical Trials and Typical Pathway.....	65
Figure 5-1.	Quality System Documentation Elements	93
Figure 5-2.	Design Control “V” Model Process Flow	94

Tables

Table 1-1	Electronic Resources for US Laws and Regulations	3
Table 1-2	Other Laws and Regulations	13
Table 2-1	Title 21 Code of Federal Regulations.....	19
Table 2-2	Summary of Device Classification System.....	24
Table 3-1	Significant Legislation Relevant to Clinical Trials in the US	38
Table 3-2	Comparison of 21 CFR and ISO GCP Requirements for Protocol Deviations in Medical Device Clinical Trials	47
Table 3-3.	Comparison of 21 CFR and ISO GCP Requirements for Investigator Responsibilities in Medical Device Clinical Trials	71
Table 3-4.	Comparison of 21 CFR and ISO-GCP Requirements for Recordkeeping in Medical Device Clinical Trials	73
Table 3-5.	Comparison of 21 CFR and ISO-GCP Requirements for Recordkeeping in Medical Device Clinical Trials	74
Table 7-1.	Key Regulatory Questions During Development	111
Table 7-2.	Key Databases for US Regulatory Information	112
Table 8-1.	Device Classification Summary of Requirements	121
Table 8-2.	Typical Data Requirements Based on Device Class.....	124
Table 8-3.	Typical Device Studies Covered Under the IDE Regulation	127
Table 9-1.	Domestic Establishments	155
Table 9-2.	Foreign Establishments.....	156
Table 9-3.	UDI Implementation Compliance Dates	163
Table 12-1.	Postmarket Safety Reporting Provisions for Combination Products	199

■ SECTION II: Fundamentals of EU Medical Device Regulations

Chapter 1:	History of EU Regulations	1	<i>Updated by Sabina L. Hoekstra-van den Bosch, PharmD, FRAPS</i>
Chapter 2:	Enforcement and Competent Authorities	13	<i>Updated by Sabina L. Hoekstra-van den Bosch, PharmD, FRAPS</i>
Chapter 3:	The New Medical Devices and In Vitro Diagnostic Devices Regulations	19	<i>Updated by Gert Bos, MSc, PhD, FRAPS and Erik Vollebregt, LLM</i>
Chapter 4:	The European Medical Devices Legal System.....	31	<i>Updated by Gert Bos, MSc, PhD, FRAPS and Erik Vollebregt, LLM</i>
Chapter 5:	Medical Devices: Legislation and Classification.....	65	<i>Updated by Ruthanne Vendy, RAC and Chauneen Leah Wood, MS, RAC</i>
Chapter 6:	In Vitro Diagnostic Medical Devices	93	<i>Updated by Sue Spencer and Erik Vollebregt, LLM</i>

Chapter 7:	General Safety and Performance Requirements and Technical Documentation: EU MDR and EU IVDR.....	109
	<i>Darin Oppenheimer, DRSc, RAC, Sapna Gbelani, MPH, RAC, and George Cusatis, MS, RAC</i>	
Chapter 8:	Medical Device Preclinical Testing.....	119
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 9:	Clinical Evaluation and Clinical Investigations	129
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 10:	Medical Device Conformity Assessment Procedure.....	137
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 11:	Medical Device Compliance: Postmarket Requirements.....	143
	<i>Updated by Tran Do and Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 12:	Medical Device National Particularities	157
	<i>Updated by Karen Zhou, JD, MS, RAC-Devices</i>	
Chapter 13:	Combination Products.....	167
	<i>Updated by Jocelyn Jennings, MS, RAC-US, RAC-Drugs, RAC-Devices</i>	
Chapter 14:	Advertising and Promotion.....	179
	<i>Jocelyn Jennings, MS, RAC-US, RAC-Drugs, RAC-Devices</i>	
Chapter 15:	Regulatory Strategys.....	191
	<i>Updated by Karen Fan, MSc, RAC, PEng, PMP</i>	
Abbreviations and Acronyms		199
Glossary of Terms.....		203
Index.....		211
Figures		
Figure 3-1	Grace Periods Under the EU IVDR.....	21
Figure 3-2	Proposed EU IVDR Classification Rules	23
Figure 3-3	Governance Structure for the EU MDR and EU IVDR	26
Figure 4-1	Simplified EU Legislative Process	33
Figure 4-2	EU MDR and EU IVDR Governance Structure	52
Figure 6-1	EU IVDR Conformity Assessment Procedures.....	94
Figure 6-2	Clinical Evidence Documentation.....	100
Tables		
Table 4-1	New Legislative Framework Areas	35
Table 4-2	EU Member States and Affiliated Countries Competent Authorities.....	39
Table 4-3	MDCG Working Groups and Their Activities.....	45
Table 4-4	European Industrial Trade Associations	45
Table 4-5	Comparison of MDD and EU MDR Definition of a Medical Device	47
Table 4-6	MDCG Guidance Documents	54
Table 5-1	EU MDR Annex VIII, Chapter III Classification Matrix	70
Table 5-2	EU IVDR Annex VIII, I Classification Matrix	72
Table 5-3	Comparison of IVD and EU IVDR Device Classification Rules.....	73
Table 5-4	EU MDR Classification Rules for Non-Invasive Medical Devices.....	78

Table 5-5	EU MDR Classification Rules for Invasive Medical Devices.....	79
Table 5-6	EU MDR Classification Rules for Active Medical Devices	80
Table 5-7	Special EU MDR Rules: Medical Devices	81
Table 5-8	Special EU MDR Rules: Medical Devices	81
Table 5-9	Comparison of MDD and EU MDR Device Classification Rules	82
Table 6-1	Examples of General Laboratory Use Products and IVD Medical Devices	96
Table 7-1	General Safety and Performance Requirements Checklist (Annex I of the EU MDR and EU IVDR)	111
Table 8-1	Basic Design Traceability Matrix (DTM) for Connecting Requirements to Test Results.....	120
Table 11-1	Provisions for Providing Feedback on Medical Devices	144
Table 11-2	Eudamed Data Repository	148
Table 11-3	Comparison of Safeguard Clause and Health Monitoring Measures	154
Table 12-1	EU Outermost Regions.....	159
Table 12-2	Current Directives and New Regulations for Medical Devices, AIMDs, and IVDs	159
Table 12-3	Translation Requirements for Medical Devices, AIMDs, and IVDs.....	160
Table 12-4	National Languages of the EU, Iceland, Liechtenstein, and Norway.....	161
Table 12-5	Medical Device Labeling Language Requirements (Including EFTA Countries)	162
Table 15-1	Key Regulatory Questions During Development.....	193

■ SECTION III: Fundamentals of International Medical Device Regulations

Chapter 1:	Introduction to International Regulatory Affairs.....	1
	<i>Updated by Rowena Cook, MS, RAC and Sharad Mi Shukla, RAC</i>	
Chapter 2:	Compliance and Enforcement	11
	<i>Updated by David W. Husman, PhD, ASQ CPGP, RAC and John Rossman, MBEE, RAC</i>	
Chapter 3:	International Counterfeit Regulations	33
	<i>Updated by Jos Kraus, PharmD, FRAPS and Siegfried Schmitt, PhD</i>	
Chapter 4:	EU Pricing and Reimbursement.....	59
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 5:	Health Technology Assessment (HTA).....	79
	<i>Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC</i>	
Chapter 6:	Medical Device Premarket Requirements.....	113
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 7:	Technical and Regulatory Requirements	135
	<i>Updated by Robin Stephens and Yuanyuan Yu</i>	
Chapter 8:	Medical Device Quality Management Systems.....	147
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 9:	In Vitro Diagnostic Medical Devices	159
	<i>Updated by Gert Bos, MSc, PhD, FRAPS and Jocelyn Jennings, MS, RAC-US, RAC-Drugs, RAC-Devices</i>	
Chapter 10:	Active Implantable Medical Devices	183
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 11:	Software	195
	<i>Updated by Raajdeep Venkatesan, MS, RAC</i>	

Chapter 12: Postmarket Requirements	209
<i>Updated by Pei-Ting S. Chou, PCQI, RAC</i>	
Chapter 13: Combination Products	219
<i>Updated by Deanna Hughes, MS, RAC and Beat U. Steffen, MSc, MBA</i>	
Abbreviations and Acronyms	237
Glossary of Terms	245
Index	253

Figures

Figure 2-1. TPLC Cycle for Devices	13
Figure 2-2. Medical Device Design Control and Review Process	17
Figure 3-1. WHO Global Monitoring System	52
Figure 4-1. Factors Influencing Medicinal Product Pricing	61
Figure 4-2. Overview of ERP Across Europe (2013)	63
Figure 4-3. Summary of Economic Evaluation Methods	65
Figure 4-4. Types of Cost Containment Policies Adopted by Member States	66
Figure 4-5. German Pricing for Medicinal Products Under AMNOG	70
Figure 5-1. Process Map for France	85
Figure 5-2. Process Map for Germany	86
Figure 5-3. Mean Length of Time From EMA Authorisation to HTA Decision for Oncology Products	89
Figure 5-4. Process Map for England	90
Figure 5-5. Process Map for Scotland	91
Figure 5-6. Historical MaHTAS Milestones	96
Figure 5-7. Flow Diagram of HTA in South Korea	98
Figure 5-8. Framework for Pricing Drugs and Devices in Japan	100
Figure 5-9. Map of Australian Government HTA Processes for Market Entry and Reimbursement Processes	101
Figure 5-10. Timeline of US “HTA Like” Bodies	102
Figure 5-11. Overview of the Canada Public System Reimbursement Decision Pathway	105
Figure 5-12. HTA Timeline in Latin America	106
Figure 6-1. Decision Tree for Noninvasive Device Classification	128
Figure 6-2. Decision Trees for Invasive Device Classification	129
Figure 6-3. Decision Tree 2 for Invasive Devices	130
Figure 6-4. Decision Tree 1 for Active Device Classification	131
Figure 6-5. Decision Tree 2 for Active Device Classification	132
Figure 6-6. Decision Tree for Device Classification With Additional Rules	133
Figure 7-1. GHTF Submission Guidance for Class A or B (Lower-Risk) Devices and Class C or D (Critical) Devices ..	137
Figure 7-2. Postmarket Use of the STED	138
Figure 8-1. Process Flow of Interrelated QMS Processes	148
Figure 8-2. PDCA Methodology	149
Figure 8-3. Requirements Clauses in ISO 13485:2016	151
Figure 8-4. Design and Development Control Steps	152
Figure 8-5. Influence of Design Controls on the Design Process	153
Figure 8-6. Process Validation Decision Tree	155
Figure 8-7. Key Activities for Supplier Control	157
Figure 9-1. Regulatory Requirements Related to the Device Risk Class	161
Figure 11-1. EU MDR Decision Tree	198

Tables

Table 2-1. Applicability of GxPs to Standardized Market Authorization Application Formats	22
Table 3-1. Definitions of Key Terms in This Chapter	35
Table 3-2. Methods to Reduce the Risk for Counterfeit and Falsification and Ensure Product Traceability	37

Table 3-3.	DSCSA Definition of Stakeholders and Key Terminology	38
Table 3-4.	FDA Timelines for Implementation of Key Plan Elements	40
Table 3-5.	Different Medicinal Product Supply Chain Stakeholder Requirements Under the FMD	45
Table 3-6.	Persons or Institutions That May Be Considered Exempt by Individual States	47
Table 3-7.	Examples of Substandard and Falsified Products Reported to the GSMS (2013-2017)	51
Table 4-1.	Overview of Reference Pricing and Country Baskets in Europe	64
Table 5-1.	Summary of Time From EMA Authorisation to HTA Decision and Outcome	84
Table 5-2.	HTA and Associated Organizations in Selected EU Member States and the UK	88
Table 5-3.	Comparison of HTA in Germany, France, UK, Italy, and Spain	92
Table 5-4.	Summary of HTA Status in Select Asian Countries	93
Table 5-5.	MaHTAS 1995–2018 Impact Overview	95
Table 5-6.	13 Selected Products for Japan MHLW 3-Year HTA Pilot Evaluation	97
Table 5-7.	Drugs Eligible for CADTH's Drug Review Processes	102
Table 5-8.	Summary of CADTH's Elements and Recommendation Categories	103
Table 5-9.	Latin American Country-Specific HTA Overview	104
Table 6-1.	Class A Device	120
Table 6-2.	Class B Device	120
Table 6-3.	Class C Device	121
Table 6-4.	Class D Device	121
Table 6-5.	Noninvasive Devices	122
Table 6-6.	Invasive Devices	123
Table 6-7.	Active Devices	126
Table 6-8.	Additional Rules	127
Table 9-1.	General GHTF Classification System for IVD Medical Devices	161
Table 9-2.	Classification Rules for IVDs	162
Table 9-3.	Classification Rules for IVDs	163
Table 9-4.	Class A Device	165
Table 9-5.	Class B Device	166
Table 9-6.	Class C Device	167
Table 9-7.	Australian Classification Scheme	176
Table 9-8.	Conformity Assessment Stages	178
Table 9-9.	Rule 9 Special Classification	179
Table 11-1.	Examples of Software Types and Their EU Qualification as General Medical Devices	205
Table 13-1.	Examples of FDA-Approved Combination Products	222
Table 13-2.	Combination Product Categories	223
Table 13-3.	Applicable Articles When the Medicinal Product is Ancillary	230
Table 13-4.	Applicable Articles for Devices to Administer Medicinal Products	232